{"id":77523,"date":"2026-08-31T14:03:26","date_gmt":"2026-08-31T06:03:26","guid":{"rendered":"https:\/\/flcube.com\/?p=77523"},"modified":"2026-08-31T14:03:27","modified_gmt":"2026-08-31T06:03:27","slug":"eli-lilly-wins-fda-approval-for-mounjaro-cardiovascular-risk-reduction-in-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77523","title":{"rendered":"Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes"},"content":{"rendered":"\n

Eli Lilly and Company<\/strong> (NYSE: LLY<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has approved Mounjaro (tirzepatide)<\/strong>, a dual GIP and GLP\u20111 hormone receptor agonist, to reduce the risk of major adverse cardiovascular events (MACE) \u2014 including cardiovascular death, non\u2011fatal heart attack, and non\u2011fatal stroke \u2014 in adults with type 2 diabetes<\/strong> at high cardiovascular risk. The label expansion strengthens Mounjaro’s position as one of the most clinically validated therapies in the diabetes and cardiometabolic space.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/td>U.S. Food and Drug Administration (FDA)<\/strong><\/td><\/tr>
Approval Type<\/td>Supplemental indication expansion<\/td><\/tr>
Product<\/td>Mounjaro (tirzepatide)<\/strong><\/td><\/tr>
Indication<\/td>Reduction of MACE (CV death, non\u2011fatal MI, non\u2011fatal stroke) in high\u2011risk adults with type 2 diabetes<\/td><\/tr>
Date<\/td>28 Aug 2026<\/td><\/tr>
Next Steps<\/td>Label update, payer and formulary engagement, continued cardiometabolic franchise expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n